Cardiac stent implantation surgery is an important measure for treating acute myocardial infarction. Previously, the average price of heart stents was as high as 13000 yuan, while the price of imported stents was close to 20000 yuan. Some patients needed to implant multiple stents, and the public strongly reflected on their inflated prices. In November 2020, the country organized a centralized procurement of high-value medical consumables, which included the first order of cardiac stents. The price of the selected products was reduced to around 700 to 800 yuan. In response to the concerns of patients about the clinical use of centralized procurement, the willingness of doctors to perform surgeries, the quality of discounted stents, and the willingness of selected manufacturers to supply, the National Medical Insurance Administration uses data on the use of centralized procurement heart stents in the past three years to clarify doubts. The National Medical Insurance Administration introduced that the discounted heart stent benefits the public by exchanging quantity for price and squeezing out intermediate costs while maintaining the original brand prototype number and process parameters. After the centralized procurement of cardiac stents, the implantation volume has been increasing year by year. 95% of doctors and patients chose the selected stent for centralized procurement. The number of medical institutions conducting cardiac stent implantation surgery has increased from over 2400 in 2020 to over 3600 in 2023, with secondary medical institutions increasing from 1200 to nearly 1700. In addition, from 2021 to 2023, the number of selected cardiac stents used was 1.6 million, 1.83 million, and 2.18 million, with an average annual growth rate of 17%, which is consistent with the growth rate of cardiac intervention surgery (10% to 25%) calculated by various calibers. More than 3.7 million patients have received selected cardiac stents. The National Medical Insurance Administration stated that the centralized procurement of heart stents is a chromium alloy drug-loaded stent that has been clinically proven to have good performance for a long time. It can better reduce the incidence of postoperative vascular restenosis and is an upgraded product of bare stents and stainless steel stents. It is also the mainstream variety currently used. From the usage data, the proportion of chromium alloy drug-loaded stents used has increased from 60% before centralized procurement to over 95%, and patients have achieved iterative upgrades using cardiac stents. The National Medical Insurance Administration also stated that after the price reduction, the manufacturer can ensure the supply volume, which reaches 1.3 times the agreed amount. From 2021 to 2023, the supply of selected heart stents after price reduction was 149%, 123%, and 123% of the agreed volume for that year, respectively. Overall, the selected manufacturers actively fulfilled their responsibilities and obligations after price reduction, and provided sufficient supply of heart stents after price reduction. The phenomenon of "only price reduction without supply" that everyone was concerned about did not occur. (Lai Xin She)